Serum 1,5-anhydroglucitol levels in patients with fulminant type 1 diabetes are lower than those in patients with type 2 diabetes.
OBJECTIVE
We investigated clinical relevance of serum 1,5-anhydroglucitol (1,5-AG) levels in fulminant type 1 diabetes mellitus (FT1DM) patients, because 1,5-AG is known to reflect short term glycemic control.


METHODS
Subjects comprised 7 patients with FT1DM and 32 patients with type 2 diabetes mellitus (T2DM) with HbA1c <8.5%. All of them have never been treated for diabetes.


RESULTS
HbA(1C) showed no significant difference between both groups. On the other hand, serum 1,5-AG levels were significantly lower in the FT1DM patients than in the T2DM patients. Serum 1,5-AG levels were < 5.0 μg/ml in 6 of 7 (86%) FT1DM patients, compared with only 1 of 32 (3%) T2DM patients.


CONCLUSIONS
Serum 1,5-AG levels were lower in the FT1DM patients than in the T2DM patients. Serum 1,5-AG, but not HbA(1C), reflects short-term exacerbation of glycemia in patients with FT1DM.
Koga
Masafumi
M
Department of Internal Medicine, Kinki Central Hospital, Hyogo, Japan. koga_m@kich.itami.hyogo.jp
Murai
Jun
J
Saito
Hiroshi
H
Mukai
Mikio
M
Kasayama
Soji
S
Imagawa
Akihisa
A
Hanafusa
Toshiaki
T
D000328:Adult; D003847:Deoxyglucose / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged
D003847:Deoxyglucose; D006442:Glycated Hemoglobin; C006584:1,5-anhydroglucitol